文献速递青光眼

局部碳酸酐酶抑制剂与青光眼2021年现状

Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
PubMed 文献 · Br J Ophthalmol · 2021-08-25

本文综述局部碳酸酐酶抑制剂(CAI)在青光眼治疗中的 prescribing 趋势、已知疗效、作用机制及对眼部血流动力学的影响。局部CAI虽处方频率低于前列腺素类似物和β受体阻滞剂,仍用于与β受体阻滞剂及α受体激动剂的联合治疗,并可改变与青光眼相关的眼部血流动力学生物标志物。

要点

  • 局部CAI处方频率低于前列腺素类似物和β受体阻滞剂,但仍用于联合治疗。
  • 局部CAI可与β受体阻滞剂及α受体激动剂联合使用。
  • 局部CAI已被证实可改变与青光眼相关的眼部血流动力学生物标志物。

核心结论

  • 局部CAI在青光眼治疗中仍有应用价值,尤其作为联合治疗组成部分,并可能通过影响眼部血流动力学参与青光眼管理。

研究设计与样本

  • 本文为综述,回顾并总结局部CAI的处方趋势、已知疗效、推测机制及对眼部血流动力学的潜在影响。

主要发现

  • 全身CAI通过减少房水生成降低眼压,但因多尿和感觉异常等频繁副作用促成了局部CAI的开发。
  • 随着局部药物发展,前列腺素类似物和β受体阻滞剂已成为青光眼治疗的金标准。
  • 局部CAI处方频率低于其他类别局部青光眼药物,但仍用于与β受体阻滞剂和α受体激动剂的联合治疗。
  • 局部CAI已被证实可改变与青光眼相关的眼部血流动力学生物标志物。

临床怎么用

  • 局部CAI可作为青光眼联合治疗方案的一部分,与β受体阻滞剂或α受体激动剂联用。
  • 临床关注局部CAI对眼部血流动力学生物标志物的影响,并将其纳入青光眼管理考量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Carbonic anhydrase inhibitors (CAIs) have been used for many decades in the treatment of glaucoma. Systemic CAIs were an early treatment option to lower intraocular pressure by reducing aqueous humour production; however, frequent side effects including polyuria and paresthesia contributed to the eventual development of topical CAIs. As topical drug development evolved over time, prostaglandin analogues and beta-blockers have become the gold standard of glaucoma therapies. Although prescribed less often than other classes of topical glaucoma therapies, topical CAIs continue to be used in combination therapies with beta-blockers and alpha agonists. Topical CAIs have also been demonstrated to alter biomarkers of ocular haemodynamics, which have relevance in glaucoma. The purpose of this review is to review and summarise the current state of topical CAI prescribing trends, known efficacy and suggested mechanisms and potential influence on ocular haemodynamics for the future of glaucoma management.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Stoner A, Harris A, Oddone F, et al. Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand? Br J Ophthalmol. 2021. PMID: 34433550. doi:10.1136/bjophthalmol-2021-319530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。